Adjuvant Therapies of Cancer

Front Matter....Pages I-XVI
Metastatic Potential of Metastases, Tumor Cell Heterogeneity, and Therapeutic Implications....Pages 1-8
Immune Imbalance and Immune Modulation in Solid Tumor Patients: New Insights....Pages 9-16
Markers of Minimal Residual Disease....Pages 17-21
Radiotherapy as Adjuvant Local Therapy of Local Tumors....Pages 22-25
Comparison of HLA Phenotypes in Long-Term Survivors with Acute Lymphoblastic Leukemia Treated with Immunotherapy Versus Chemotherapy....Pages 26-28
An Intensive Chemo- or Chemoimmunotherapy Regimen for Patients with Intermediate and Poor-Prognosis Acute Lymphatic Leukemia and Leukemic Lymphoblastic Lymphosarcoma: Preliminary Results with 14-Month Median Follow-Up....Pages 29-35
Poor-Prognosis Acute Lymphoblastic Leukemias....Pages 36-41
Therapeutic Effectiveness of Neuraminidase-Treated Allogeneic Myeloblasts as Immunogen in Acute Myelocytic Leukemia....Pages 42-55
Maintenance Chemoimmunotherapy of Nonlymphoblastic Acute Leukemias....Pages 56-63
Possible Mechanisms of Immunotherapy Action in Acute Nonlymphatic Leukemia: Macrophage Production of Colony-Stimulating Activity....Pages 64-69
The Finnish Leukaemia Group: Levamisole in Maintenance Therapy of Acute Myeloid Leukemia in Adults....Pages 70-72
Treatment of Acute Leukemia in Remission by Bone Marrow Transplantation....Pages 73-77
Prevention of Blastic Crisis in Ph 1 -Positive Chronic Myeloid Leukemia....Pages 78-82
A Southwest Oncology Group: Chemotherapy Versus Chemotherapy Plus Radiotherapy in Treatment of Stage III Hodgkin’s Disease....Pages 83-91
Maintenance Immunotherapy with BCG in Non-Hodgkin’s Malignant Lymphomas: A Progress Report of a Randomized Trial....Pages 92-97
Role of Lung Irradiation in the Adjuvant Treatment of Osteosarcoma....Pages 98-102
Adjuvant Interferon Treatment of Human Osteosarcoma....Pages 103-107
A Strategic Adjuvant Therapy of Osteosarcoma....Pages 108-114
Ewing’s Sarcoma: Treatment with High-Dose Radiation and Adjuvant Chemotherapy....Pages 115-119
Adjuvant Chemotherapy in Ewing’s Sarcoma Patients....Pages 120-123
Early Results of Combined Modality Therapy of Patients with Ewing’s Sarcoma....Pages 124-127
Ewing’s Sarcoma: 5-Year Survival Under Adjuvant Chemotherapy....Pages 128-133
Natural History of Breast Cancer....Pages 134-141
Adjuvant Chemotherapy in Breast Cancer....Pages 142-148
Multimodal Therapy with CMF in Resectable Breast Cancer with Positive Axillary Nodes: The Milan Institute Experience....Pages 149-156
Follow-Up Results from a Randomized Trial for T 3 and T 4 Breast Cancer Patients: Previous BCG Immunotherapy Improves Response to Chemotherapy in the Relapse Patient....Pages 157-161
Adjuvant Treatment of Node-Positive Breast Cancer with Adriamycin-Cyclophosphamide with or Without Radiation Therapy: Interim Results of an Ongoing Clinical Trial....Pages 162-169
A Randomized Trial of Postoperative Five-Versus Three-Drug Chemotherapy After Mastectomy: A Cancer and Leukemia Group B (CALGB) Study....Pages 170-176
Adjuvant Chemoimmunotherapy with LMF Plus BCG in Node-Negative and Node-Positive Breast Cancer — Intermediate Report at 4 Years....Pages 177-184
Adjuvant Intermittent Chemoimmunotherapy for Primary Breast Cancer: A Prospective Study with Immunologic Follow-Up....Pages 185-191
Short-Term and Long-Term Effects of Chemoimmunotherapy on Granulopoiesis: Adjuvant Therapy of Breast Cancer....Pages 192-199
A New Adjuvant Treatment with PolyadenyliC-Polyuridylic Acid in Operable Breast Cancer....Pages 200-206
Metastatic CNS Disease in Small Cell Carcinoma of the Bronchus: The Role of Radiotherapy and Chemotherapy....Pages 207-213
Interim Results of EORTC Protocol 08742: Comparison, After Irradiation of Locally Advanced Squamous Cell Bronchial Carcinoma, of Abstention, Immunotherapy, Combination Chemotherapy, or Chemoimmunotherapy....Pages 214-218
Immunologically Defined Prognostic Subgroups as Predictors of Response to BCG Immunotherapy....Pages 219-226
Intrapleural BCG Immunotherapy of Lung Cancer Patients....Pages 227-231
Specific Active Immunotherapy in Lung Cancer: The Induction of Long-Lasting Cellular Responses to Tumour-Associated Antigens....Pages 232-239
Malnutrition in Lung Cancer: Incidence, Prognostic Implications, and Pathogenesis....Pages 240-245
Follow-Up of a Randomized Trial for Oat Cell Carcinoma Evaluating the Efficacy of Peripheral Intravenous Nutrition (PIVN) as Adjunct Treatment....Pages 246-253
Clinical Trials of Chemotherapy and Chemoimmunotherapy in Primary Malignant Melanoma....Pages 254-258
Trial 6: Randomized Study of Prolonged Chemotherapy, Immunotherapy, and Chemoimmunotherapy as an Adjuvant to Surgery for Stage I and II Melanoma: A Progress Report....Pages 259-263
Current Status of Melanoma Chemotherapy and Immunotherapy....Pages 264-268
Adjuvant Therapy of Testicular Carcinoma....Pages 269-276
Adjuvant 5-Fluorouracil and BCNU Chemotherapy in Gastric Cancer: 3-Year Results....Pages 277-283
Adjuvant Chemotherapy in Colon and Gastric Cancer....Pages 284-290
Chemotherapy of Metastatic Gastrointestinal Cancers: Prospects for Future Adjuvant Systemic Therapies....Pages 291-295
Chemotherapy of Carcinomas of the Digestive Tract....Pages 296-302
Clinical Trials on Adjuvant Therapies in Cancer: Short-Term and Long-Term Results....Pages 303-308
Long-Term Costs of Adjuvant Radiotherapy....Pages 309-311
Long-Term Cost of Combined Radiotherapy and Chemotherapy....Pages 312-316
Studies of Clonogenic Human Tumor Stem Cells....Pages 317-322
Current Status of Clinical Trials of m-AMSA, Dihydroxyanthracenedione, and Deoxycoformycin....Pages 323-330
Three New Agents for Immunotherapy Trials: Azimexon, Bestatin, and Tuftsin....Pages 331-333
Emerging Immunologic Approaches, to Treatment of Neoplastic Diseases....Pages 334-337
Cellular Interactions Modulating Host Resistance to Tumours....Pages 338-345
Preliminary Clinical Results with Norgamem (Thioproline) and Revercan (2-Amino-2-Thiazoline): The First Inducers of Reverse Transformation....Pages 346-350
Biologic-Response Modifiers and Adjuvant Chemotherapy: Consideration of Selected Preclinical Investigations in Relation to Clinical Potential....Pages 351-356
Back Matter....Pages 357-358